Janus 激酶 3：调控者与被调控者。
Janus kinase 3: the controller and the controlled.
机构信息
Immunobiology and Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, 73104, USA.
出版信息
Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):187-96. doi: 10.1093/abbs/gmr105. Epub 2011 Nov 29.
Abstract
Janus kinase (JAK)-signal transducer and activators of transcription (STAT) signaling pathways play crucial roles in lymphopoiesis. In particular, JAK3 has unique functions in the lymphoid system such that JAK3 ablation results in phenotypes resembling severe combined immunodeficiency syndrome. This review focuses on the biochemistry, immunological functions, and clinical significance of JAK3. Compared with other members of the JAK family, the biochemical properties of JAK3 are relatively less well characterized and thus largely inferred from studies of JAK2. Furthermore, new findings concerning the cross-talks between Notch and JAK signaling pathways through ubiquitin-mediated protein degradation are discussed in more detail.
摘要
Janus 激酶（JAK）-信号转导子和转录激活子（STAT）信号通路在淋巴发生中起着至关重要的作用。特别是，JAK3 在淋巴系统中具有独特的功能，因此 JAK3 缺失会导致类似于严重联合免疫缺陷综合征的表型。本综述重点介绍 JAK3 的生物化学、免疫学功能和临床意义。与 JAK 家族的其他成员相比，JAK3 的生化特性相对较差，因此主要是从 JAK2 的研究中推断出来的。此外，还更详细地讨论了 Notch 和 JAK 信号通路通过泛素介导的蛋白质降解相互作用的新发现。
相似文献
1
Janus kinase 3: the controller and the controlled.
Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):187-96. doi: 10.1093/abbs/gmr105. Epub 2011 Nov 29.
2
A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation.
J Biol Chem. 2011 Dec 2;286(48):41153-41162. doi: 10.1074/jbc.M111.273755. Epub 2011 Oct 3.
3
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
J Biol Chem. 2002 Dec 6;277(49):47954-63. doi: 10.1074/jbc.M205156200. Epub 2002 Sep 25.
4
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.
5
Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Int J Mol Sci. 2024 Mar 4;25(5):2977. doi: 10.3390/ijms25052977.
6
Role of JAK1, JAK2, and JAK3 in Functional Stimulation of Mesenchymal Precursor Cells by Alkaloid Songorine.
Bull Exp Biol Med. 2017 Aug;163(4):443-446. doi: 10.1007/s10517-017-3824-9. Epub 2017 Aug 29.
7
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Expert Opin Ther Pat. 2013 Apr;23(4):449-501. doi: 10.1517/13543776.2013.765862. Epub 2013 Feb 1.
8
The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Bioorg Med Chem. 2016 Nov 1;24(21):5036-5046. doi: 10.1016/j.bmc.2016.08.008. Epub 2016 Aug 6.
9
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Circulation. 2018 May 1;137(18):1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423. Epub 2017 Dec 18.
10
JAK and MPL mutations in myeloid malignancies.
Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360.
引用本文的文献
1
Apoptosis and eryptosis: similarities and differences.
Apoptosis. 2024 Apr;29(3-4):482-502. doi: 10.1007/s10495-023-01915-4. Epub 2023 Nov 30.
2
Janus Kinase 3 Deficiency Promotes Vascular Reendothelialization-Brief Report.
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):2019-2026. doi: 10.1161/ATVBAHA.121.316293. Epub 2021 Apr 29.
3
The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture.
Arch Rheumatol. 2020 Feb 7;35(3):343-350. doi: 10.46497/ArchRheumatol.2020.7568. eCollection 2020 Sep.
4
Understanding the structural features of JAK2 inhibitors: a combined 3D-QSAR, DFT and molecular dynamics study.
Mol Divers. 2019 Nov;23(4):845-874. doi: 10.1007/s11030-018-09913-4. Epub 2019 Jan 7.
5
Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.
Int J Nanomedicine. 2018 Aug 27;13:4817-4830. doi: 10.2147/IJN.S161932. eCollection 2018.
6
JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.
Mol Genet Genomic Med. 2018 Sep;6(5):713-721. doi: 10.1002/mgg3.391. Epub 2018 Jul 21.
7
Janus Kinase 3, a Novel Regulator for Smooth Muscle Proliferation and Vascular Remodeling.
Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1352-1360. doi: 10.1161/ATVBAHA.116.308895. Epub 2017 May 4.
8
The brain parenchyma has a type I interferon response that can limit virus spread.
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E95-E104. doi: 10.1073/pnas.1618157114. Epub 2016 Dec 15.
9
Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized Receptor.
Mol Cell Biol. 2015 Sep;35(18):3131-44. doi: 10.1128/MCB.00286-15. Epub 2015 Jun 29.
10
Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.
Biomed Res Int. 2015;2015:318364. doi: 10.1155/2015/318364. Epub 2015 Mar 1.
本文引用的文献
1
Targeting JAK3 in kidney transplantation: current status and future options.
Curr Opin Organ Transplant. 2011 Dec;16(6):614-9. doi: 10.1097/MOT.0b013e32834c23ce.
2
A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation.
J Biol Chem. 2011 Dec 2;286(48):41153-41162. doi: 10.1074/jbc.M111.273755. Epub 2011 Oct 3.
3
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Arthritis Rheum. 2012 Mar;64(3):617-29. doi: 10.1002/art.33383.
4
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
Blood. 2011 Oct 6;118(14):3911-21. doi: 10.1182/blood-2010-12-319467. Epub 2011 Aug 5.
5
An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation.
Int Immunol. 2011 Jul;23(7):415-20. doi: 10.1093/intimm/dxr029. Epub 2011 Jun 1.
6
Advances in rheumatology: new targeted therapeutics.
Arthritis Res Ther. 2011 May 25;13 Suppl 1(Suppl 1):S5. doi: 10.1186/1478-6354-13-S1-S5.
7
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Arthritis Care Res (Hoboken). 2011 Aug;63(8):1150-8. doi: 10.1002/acr.20494.
8
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.
Nature. 2011 May 12;473(7346):230-3. doi: 10.1038/nature09999.
9
Notch-induced Asb2 expression promotes protein ubiquitination by forming non-canonical E3 ligase complexes.
Cell Res. 2011 May;21(5):754-69. doi: 10.1038/cr.2010.165. Epub 2010 Nov 30.
10
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Blood. 2010 Feb 4;115(5):1006-17. doi: 10.1182/blood-2009-08-235408. Epub 2009 Nov 24.
Zotero 插件